Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099 7/04/2026

130,90 USD (-1,19%)

(-1,19%) 7/04/2026

Grafiek Neurocrine Biosciences, Inc.

Grafiek Neurocrine Biosciences, Inc.

1 dag1d -1,19%
1 week1w -1,25%
1 maand1m 0,75%
3 maanden3m -3,44%
6 maanden6m -5,88%
1 jaar1j 49,53%
5 jaar5j 41,22%

Neurocrine Biosciences, Inc. in het nieuws

Toon enkel gratis nieuws

26 maart 2026 · Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings · Persbericht

17 maart 2026 · Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer · Persbericht

10 maart 2026 · Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum · Persbericht

6 maart 2026 · BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX) · Persbericht

24 februari 2026 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in March · Persbericht

11 februari 2026 · Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 · Persbericht

26 januari 2026 · Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia · Persbericht

21 januari 2026 · Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results · Persbericht

15 januari 2026 · Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR · Persbericht

5 januari 2026 · Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference · Persbericht

Profiel Neurocrine Biosciences, Inc.

Gezondheidstechnologie

Productie van biologische producten

Website: www.neurocrine.com

Hoofdzetel: San Diego, California Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe